Malignant eccrine spiradenoma with squamoid and chondroid differentiation

Abstract

Malignant eccrine spiradenoma (MES) is an extremely rare sweat gland tumor that arises in a pre-existing benign eccrine spiradenoma. We describe a case of malignant eccrine spiradenoma of a 41-year-old male with a history of swelling over nape of neck for 6yrs and recent onset of increase in size since 6 months. Microscopically, the tumour showed benign component, which was composed of 2 nodules with interwining bands of 2 types of epithelium- inner differentiated cuboidal cells and peripheral undifferentiated cells. Malignant component was composed of large clear cells with areas of Squamoid and Chondroid differentiation, lymph nodes showed metastasis. With all these features, a diagnosis of malignant eccrine spiradenoma with Squamoid and Chondroid differentiation was made.

Keywords: malignant eccrine spiradenoma, skin tumour, differentiation

Introduction

Malignant eccrine spiradenoma (MES) is an extremely rare sweat gland tumor. It may develop de novo (malignant eccrine poroma or mucinous carcinoma) or arise in pre-existing benign eccrine spiradenoma. However most tumors are presented in the latter mode. It usually presents as a small, firm, reddish painful and small solitary nodule. Etiology is unknown although previous trauma is believed to be an implicated factor. In this report, we present an additional case of malignant eccrine spiradenoma diagnosed on 41 year old male which arises in a very unusual location with a peculiar histopathology.

Case summary

A 41 years male patient, presented with a history of swelling over nape of neck for 6 yrs and recent onset of increase in size since 6months. Patient underwent complete excision. Grossly, mass appeared grey white measuring 1.7cm in diameter. On microscopy, nodules of benign adnexal tumour undergoing malignant transformation (Figure 1) were noted. Benign component is composed of 2 nodules with interwining bands of 2 types of epithelium- inner differentiated cuboidal cells and peripheral undifferentiated cells. Malignant component was composed of large clear cells with areas of Squamoid (Figure 4) and Chondroid (Figure 5) differentiation, lymph nodes showed metastasis. With all these features, a diagnosis of malignant eccrine spiradenoma with Squamoid and Chondroid differentiation was made.

Figure 1 Nodule of benign adnexal tumor undergoing malignant transformation (X10).

Figure 2 Benign component is composed of interwining bands with two types of epithelial cells: inner differentiated cuboidal cells and peripheral undifferentiated cells with dark nuclei (X40).

Figure 3 Large polygonal and spindle cells with vesicular nuclei (X40).

Figure 4 Areas of Squamoid differentiation (X40).
Conclusion

Malignant eccrine spiradenoma with Squamoid and Chondroid differentiation with nodal metastasis is extremely rare. Morphological differentiation in malignant eccrine spiradenoma is variable, sometimes with almost complete loss of eccrine differentiation. Wide resection may be curative, but recurrences and metastases are frequent. Neither chemotherapy nor radiotherapy seems to control the progression of the disease. However, it is very difficult to determine the optimal therapeutic approaches because of the rarity of this lesion.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References

1. Chou SC, Lin SL, Tseng LH. Malignant eccrine spiradenoma: a case report with pulmonary metastasis. Pathol Int. 2004;54(4):208–212.
2. Nadig SK, Alderdice JM, Adair RA, et al. Eccrine spiradenoma: an unusual presentation with otalgia. Otolaryngol Head Neck Surg. 2004;130(2):277–278.
3. Fernández-Aceñero MJ, Manzarbeitia F, Mestre de Juan MJ, et al. Malignant spiradenoma: report of two cases and literature review. J Am Acad Dermatol. 2004;44(2 Suppl):395–398.
4. Leach BC, Graham BS. Papular lesion of the proximal nail fold-Eccrine spiradenoma. Arch Dermatol. 2004;140(8):1003–1008.
5. Dabska M. Malignant transformation of eccrine spiradenoma. Pol Med J. 1972;11(12):388–396.
6. Mizra I, Kloss R, Sieber SC. Malignant eccrine spiradenoma. Arch Pathol Lab Med. 2004;126(5):591–594.
7. Ishikawa M, Nakanishi Y, Yamazaki N, et al. Malignant eccrine spiradenoma: a case report and review of the literature. Dermatol Surg. 2001;27(1):67–70.
8. Singhal N, Bansal C, Punia RS, et al. Malignant eccrine spiradenoma: a case report. Eodj. 2001;5(2):1–13.
9. Fernández-Aceñero MJ, Manzarbeitia F, Mestre de Juan MJ, et al. Malignant spiradenoma: report of two cases and literature review. J Am Acad Dermatol. 2001;44(2 Suppl):395–398.
10. Meyer TK, Rhee JS, Smith MM, et al. External auditory canal eccrine spiradenocarcinoma: a case report and review of the literature. Head Neck. 2003;25(6):505–510.
11. Herzberg AJ, Elenitsas R, Strohmeyer CR. An unusual case of early malignant transformation in a spiradenoma. Dermatol Surg. 1995;2(8):731–734.
12. Morris DM, Sansui ID, Laneheart WH. Carcinoma of eccrine sweat gland: experience with chemotherapy, autopsy findings in a patient with metastatic eccrine carcinoma and a review of literature. J Surg Oncol. 1986;31(1):26–30.

Figure 5 Areas of chondroid differentiation (X40).

Discussion

In 1972 Dabska reported the first case of malignant transformation of eccrine spiradenoma, which is an extremely rare tumor that arises from preexisting eccrine spiradenoma. It is an uncommon tumor that occurs in young adult without any sex predilection. The tumor usually presents as a solitary firm round dermal nodule on any part of the body but most frequently on face, scalp, trunk and proximal parts of limbs. The average size of malignant eccrine spiradenoma at presentation is 3.9cm (range 0.5–15cm). The malignant eccrine spiradenoma almost always arises from a preexisting benign eccrine spiradenoma after a variable latent period, which may be as long as 75years. It generally begets medical attention when a pre-existing undiagnosed lesion rapidly enlarges, changes color, ulcerates, or becomes painful and tender. Malignant eccrine spiradenoma metastasizes to regional lymph nodes, lungs, brain, and liver (in descending order of frequency). Management depends on proper diagnosis which is based on histopathologically findings. Histopathologically, proliferation of cells with hyper chromatic nuclei, increased mitoses, loss of Periodic Acid-Schiff positive basement membrane cords and invasion of the surrounding tissues characterize malignant transformation in eccrine spiradenoma. It shows focal squamous differentiation, which may be florid in rare instances. Less frequently, areas of spiradenoma near or in transition with a malignant tumor such as rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, and chondrosarcoma may be present. Immunohistochemical, malignant eccrine spiradenoma exhibit variable expression of cytokeratins, carcinoembryonic antigen, epithelial membrane antigen and S100 protein. Over expression of p53 protein in benign spiradenoma has been associated with malignant transformation, usually into a carcinoma. However, carcinosarcomatous transformation has also been reported. Radiation therapy has little role in the management of sweat gland tumors. These lesions are rare so the experience with chemotherapy is limited. Symptomatic improvement and shrinkage of the tumor with tamoxifen therapy in a patient with estrogen receptor positive eccrine adenocarcinoma has also been reported. Recurrences after treatment are frequent and often occur after incomplete tumor excisions. Hence, aggressive surgical treatment must be performed.